Sinphar Pharmaceutical (Taiwan) Today
| 1734 Stock | TWD 31.15 0.05 0.16% |
Performance0 of 100
| Odds Of DistressLess than 34
|
Sinphar Pharmaceutical is selling for under 31.15 as of the 26th of November 2024; that is 0.16 percent increase since the beginning of the trading day. The stock's lowest day price was 31.05. Sinphar Pharmaceutical has about a 34 percent probability of financial distress in the next few years of operation and has generated negative returns over the last 90 days. Sinphar Pharmaceutical has reported 1000 for 1080 split on 4th of September 2024. Equity ratings for Sinphar Pharmaceutical Co are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 27th of October 2024 and ending today, the 26th of November 2024. Click here to learn more.
,Ltd., together with its subsidiaries, researches, develops, manufactures, and sells therapeutic drugs, health care foods, and medical beauty products in Taiwan and internationally. ,Ltd. was founded in 1977 and is headquartered in Yilan, Taiwan. SINPHAR PHARMACEUTICAL operates under Biotechnology classification in Taiwan and is traded on Taiwan Stock Exchange.. The company has 167.72 M outstanding shares. More on Sinphar Pharmaceutical Co
Moving together with Sinphar Stock
| 0.78 | 1438 | SanDi Properties | PairCorr |
| 0.7 | 1516 | Falcon Power Split | PairCorr |
| 0.82 | 6785 | Alar Pharmaceuticals | PairCorr |
| 0.67 | 1423 | Reward Wool Industry | PairCorr |
| 0.62 | 3465 | New Advanced Electronics | PairCorr |
Moving against Sinphar Stock
Sinphar Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Sinphar Pharmaceutical's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Sinphar Pharmaceutical or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Chairman of the Board | Zhiwen Li |
| Business Concentration | Health Care, Pharmaceuticals, Biotechnology, Healthcare (View all Sectors) |
Sinphar Pharmaceutical Co (1734) is traded on Taiwan Stock Exchange in Taiwan and employs 26 people. The company currently falls under 'Mid-Cap' category with a current market capitalization of 5.4 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Sinphar Pharmaceutical's market, we take the total number of its shares issued and multiply it by Sinphar Pharmaceutical's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Sinphar Pharmaceutical operates under Pharmaceuticals sector and is part of Health Care industry. The entity has 167.72 M outstanding shares.
Sinphar Pharmaceutical Co has accumulated about 937.43 M in cash with 135.54 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.59.
Check Sinphar Pharmaceutical Probability Of Bankruptcy
Ownership AllocationSinphar Pharmaceutical shows a total of 167.72 Million outstanding shares. Sinphar Pharmaceutical maintains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Sinphar Ownership Details
Sinphar Pharmaceutical Risk Profiles
Although Sinphar Pharmaceutical's alpha and beta are two of the key measurements used to evaluate Sinphar Pharmaceutical's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 0.8575 | |||
| Standard Deviation | 1.97 | |||
| Variance | 3.88 | |||
| Risk Adjusted Performance | (0.08) |
Sinphar Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Sinphar Pharmaceutical without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Portfolio Volatility Now
Portfolio VolatilityCheck portfolio volatility and analyze historical return density to properly model market risk |
| All Next | Launch Module |
Additional Tools for Sinphar Stock Analysis
When running Sinphar Pharmaceutical's price analysis, check to measure Sinphar Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sinphar Pharmaceutical is operating at the current time. Most of Sinphar Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Sinphar Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sinphar Pharmaceutical's price. Additionally, you may evaluate how the addition of Sinphar Pharmaceutical to your portfolios can decrease your overall portfolio volatility.